Real-world Evidence: Managing Platelet Counts in Ovarian Cancer Patients on First-Line Maintenance Niraparib
Posted innews OB/GYN & Women’s Health Oncology

Real-world Evidence: Managing Platelet Counts in Ovarian Cancer Patients on First-Line Maintenance Niraparib

A US cohort study of 543 ovarian cancer patients revealed 37% experienced decreased platelets during niraparib maintenance. Onset typically occurred within 1 month but resolved rapidly with dose adjustments, resulting in low discontinuation rates (16%). However, discontinuations often lacked prior dose modification, indicating management optimization opportunities.
Adding Ipilimumab to Brentuximab Vedotin Plus Nivolumab Did Not Improve Complete Response, but May Prolong Disease Control Without Transplant in Relapsed Hodgkin Lymphoma
Posted inHematology-Oncology news Oncology

Adding Ipilimumab to Brentuximab Vedotin Plus Nivolumab Did Not Improve Complete Response, but May Prolong Disease Control Without Transplant in Relapsed Hodgkin Lymphoma

In randomized phase 2 E4412, BV/ipilimumab/nivolumab did not significantly improve complete response or overall PFS versus BV/nivolumab, but showed a notable signal for longer disease control among patients who did not undergo stem cell transplantation.
Radiation-Induced OME: Bacterial Colonization Elevates Early Recurrence Risk Yet Lacks Long-Term Prognostic Value
Posted innews Oncology Otorhinolaryngology

Radiation-Induced OME: Bacterial Colonization Elevates Early Recurrence Risk Yet Lacks Long-Term Prognostic Value

Radiation-induced otitis media with effusion (RI-OME) shows heightened bacterial colonization with opportunistic pathogens. Although microbial presence predicts early recurrence (≤4 weeks post-tympanocentesis), it does not independently influence 24-week outcomes, questioning the role of antibacterial prophylaxis in NPC survivors.